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Objectives This study sought to prospectively investigate the longitudinal effects of continuous-flow left ventricular assist
device (LVAD) unloading on myocardial structure and systolic and diastolic function.
Background The magnitude, timeline, and sustainability of changes induced by continuous-flow LVAD on the structure and
function of the failing human heart are unknown.
Methods Eighty consecutive patients with clinical characteristics consistent with chronic heart failure requiring implantation of a
continuous-flow LVAD were prospectively enrolled. Serial echocardiograms (at 1, 2, 3, 4, 6, 9, and 12months) and right
heart catheterizations were performed after LVAD implant. Cardiac recovery was assessed on the basis of improvement in
systolic and diastolic function indices on echocardiography that were sustained during LVAD turn-down studies.
Results After 6 months of LVAD unloading, 34% of patients had a relative LV ejection fraction increase above 50% and
19% of patients, both ischemic and nonischemic, achieved an LV ejection fraction 40%. LV systolic function
improved as early as 30 days, the greatest degree of improvement was achieved by 6 months of mechanical
unloading and persisted over the 1-year follow up. LV diastolic function parameters also improved as early as 30
days after LVAD unloading, and this improvement persisted over time. LV end-diastolic and end-systolic volumes
decreased as early as 30 days after LVAD unloading (113 vs. 77 ml/m2, p  0.01, and 92 vs. 60 ml/m2, p  0.01,
respectively). LV mass decreased as early as 30 days after LVAD unloading (114 vs. 95 g/m2, p  0.05) and contin-
ued to do so over the 1-year follow-up but did not reach values below the normal reference range, suggesting no atro-
phic remodeling after prolonged LVAD unloading.
Conclusions Continuous-flow LVAD unloading induced in a subset of patients, both ischemic and nonischemic, early improve-
ment in myocardial structure and systolic and diastolic function that was largely completed within 6 months,
with no evidence of subsequent regression. (J Am Coll Cardiol 2013;61:1985–94) © 2013 by the
American College of Cardiology Foundation
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LVAD Unloading Effects on Cardiac Function May 14, 2013:1985–94Left-ventricular assist devices
(LVAD) are increasingly used to
“bridge” end-stage heart failure
(HF) patients to heart transplanta-
tion or as permanent (“destination”)
therapy (1,2). Whereas their utility
in increasing cardiac output and
reversing end-organ damage is
established, there is uncertainty
regarding the consequences of this
intervention on myocardial struc-
ture and function. In chronic HF,
cardiac remodeling is driven in
large part by pressure and volume overload on the left
ventricle (LV) (3). Studies performed mostly with first-
eneration pulsatile LVAD suggest that mechanical un-
oading can result in improvement in myocardial struc-
ure and function, and some patients can be weaned from the
echanical support with sustained myocardial recovery (4–9).
See page 1995
However, the results of these studies on LVAD-induced
reverse remodeling and cardiac recovery were variable and
inconclusive for several reasons that we have recently sum-
marized (10): 1) small size of studies; 2) retrospective design
of most studies; 3) nonstandardized monitoring of heart
function during LVAD support; 4) variations in the dura-
tion of LVAD unloading; 5) drugs concurrent to LVAD
therapy varied and were not documented; 6) divergences in
cardiac recovery criteria/LVAD weaning criteria; and 7) diver-
sity of the populations studied with respect to propensity for
cardiac recovery (extent of pre-LVAD cardiac remodeling,
HF etiology, inclusion of both acute and chronic HF
patients, etc.). These issues have led to skepticism as to
whether pulsatile LVAD-induced myocardial recovery is a
“real” and consistent phenomenon or an anecdotal experi-
ence (10,11).
The chronic mechanical circulatory support field has
meanwhile shifted to second-generation, continuous-flow
LVAD. Compared with pulsatile LVAD, these newer
devices produce a qualitatively different type of unloading
(10,12–15). Large-scale trials that evaluated the clinical
effectiveness of chronic continuous-flow LVAD unloading
as a bridge to transplantation or destination therapy were
primarily focused on morbidity, mortality, and changes in
end-organ function, and they did not include evaluation of
serial myocardial functional or structural data (1,2,16–18).
As a consequence, the longitudinal effects on the myocardial
function and structure induced by continuous-flow LVAD
are largely unknown.
In this prospective study, we evaluated the effects of
continuous-flow mechanical unloading on the structure and
systolic and diastolic function of the failing human heart.
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
LA  left atrium
LV  left ventricle
LVAD  left ventricular
assist device(s)
LVEF  left ventricular
ejection fraction
RV  right ventricleOur aim was to derive homogeneous and comprehensivedata from an LVAD population of a considerable size in
order to investigate the natural history of continuous-flow
mechanical unloading on the failing human heart.
Methods
Study population. We prospectively enrolled 90 consecu-
tive patients with HF who required circulatory support with
a continuous-flow LVAD as a bridge to transplantation or
destination therapy between 2008 and 2011. The patients
were enrolled at the institutions comprising the Utah Trans-
plantation Affiliated Hospitals Cardiac Transplant program
(University of Utah Health Science Center, Intermountain
Medical Center and the Veterans Administration Salt Lake
City Health Care System, all in Salt Lake City, Utah).
Duration of HF history was defined as the time from HF
symptoms onset to enrollment. Patients without a previous
history of chronic HF who required LVAD support due to
acute HF (acute myocardial infarction, acute myocarditis,
post-cardiotomy cardiogenic shock, etc.) were not included
in the current analysis (n  8). By doing so, we eliminated
a group of patients with a likely higher propensity for
“natural” cardiac recovery. Patients with infiltrative forms
of heart disease, hypertrophic cardiomyopathy, and HF
with preserved systolic function were also excluded (n 2). The
remaining 80 patients formed our study cohort. The pa-
tients were medically managed at the discretion of the
physicians of the Utah Transplantation Affiliated Hospitals
Cardiac Transplant Program. Informed consent was ob-
tained from all patients, and the study was approved by the
institutional review board of the participating institutions.
Study procedures. Clinically relevant data, including de-
mographics, medications, comorbidities, and laboratory
data, were collected up to 24 h prior to LVAD implanta-
tion. Right heart catheterization data were obtained within
1 week preceding LVAD implantation and between 6 and 8
weeks after implantation.
After LVAD implantation, the device speed was adjusted
to achieve adequate flows (cardiac output) and LV decom-
pression while maintaining a pulsatility index 3.5 when-
ever possible. (Pulsatility index was calculated through the
following calculation: [(maximum pump flow – minimum
pump flow)/average flow] 10. Pump flow is an estimate of
blood flow through the pump based on the rotor speed and
the pump power in watts.) Although adjustments of LVAD
speed were performed on an individual basis, in general, the
speed during the first 24 h was increased under echocardio-
graphic guidance to allow for aortic valve opening with a
ratio of approximately 1:3. Subsequently and prior to
discharge, LVAD speed was optimized based on patient
symptoms and clinical events (e.g., suction events).
Short- and long-term complications observed during
LVAD support (either related or unrelated to the LVAD
therapy) were prospectively captured using the standardized
INTERMACS (Interagency Registry for Mechanically As-
sisted Circulatory Support) definitions (19). Complications
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bleeding, hemolysis, right heart failure, cardiac arrhyth-
mia, device malfunction, hypertension, major infection,
renal dysfunction, hepatic dysfunction, respiratory fail-
ure, myocardial infarction, and neurological dysfunction.
Echocardiographic examinations were performed at the
echocardiography laboratories of the participating institu-
tions and stored digitally. The echocardiograms were per-
formed within 2 weeks preceding LVAD implantation, and
then at months 1, 2, 3, 4, 6, 9, and 12 after implantation.
Per our standard clinical protocol, patients underwent post-
LVAD echocardiographic examinations: 1) with full sup-
port of the LVAD, that is, at revolutions per min selected to
provide optimal hemodynamic support; and 2) with mini-
mal LVAD support (turn-down study). The first set of
echocardiographic images was obtained while the LVAD
was providing full support. Subsequently, the speed of the
LVAD was gradually reduced to the lowest setting recom-
mended by the manufacturer, and a second set of echocar-
diographic images was obtained approximately 30 min later
(“turn-down study”) (20). The effectiveness of LV reloading
was assessed by aortic valve opening during cardiac systole.
After the completion of each echocardiographic study,
the speed of the LVAD was set to the level judged by the
treating HF physician as most appropriate based on the
patients’ symptoms and other clinical characteristics. The turn-
down echocardiographic studies were performed only on
therapeutic international normalized ratio (2.0 to 3.0).
Turn-down echocardiographic studies were not performed
in patients with a history of stroke/transient ischemic attack,
LVAD thrombosis, hemolysis, difficulties in achieving op-
timal anticoagulation, or during subtherapeutic interna-
tional normalized ratio.
Echocardiographic studies included complete 2-dimensional,
M-mode, and Doppler (color, spectral, and tissue) exami-
nations. LV wall thickness, internal dimensions, and their
derivatives LV mass and fractional shortening were obtained
from 2-dimensional echocardiographic images using a pre-
viously described technique in accordance with current
American Society of Echocardiography guidelines (21).
Assessment of LV volumes and LV ejection fraction
(LVEF) was performed using the apical 4- and 2-chamber
views. The endocardial border at both end-systole and
end-diastole was manually traced, and both volumes deter-
mined using the biplane modified Simpson formula (21).
Right ventricular (RV) size was evaluated by means of RV
dimensions obtained at end-diastole from a RV-focused
apical 4-chamber view (basal RV end-diastolic dimension)
and from a parasternal long-axis views (RV outflow tract).
Similarly, left atrial (LA) dimensions and volumes were
measured according to current American Society of Echo-
cardiography guidelines. Volumes, linear dimensions, and
LV mass were indexed to the patients’ body surface area.
Doppler evaluation included the assessment of mitral inflow
velocities and tissue mitral annular velocities obtained from
an apical 4-chamber view and using pulsed-wave Doppler.For the evaluation of tissue annular velocities, the sample
volume was positioned at or 1 cm within the septal and
lateral insertion sites of the mitral valve leaflets to cover the
longitudinal excursion of the mitral annulus in both systole
and diastole. Spectral Doppler assessment of the mitral
inflow velocities and annular tissue velocities was carried out
at sweep speeds of 50 to 100 mm/s at end-expiration and
the measurements were an average of 3 consecutive
cardiac cycles. Mitral inflow parameters evaluated included
early mitral inflow velocity (E-wave), late or atrial mitral
inflow velocity (a-wave), and E-wave deceleration time.
Tissue Doppler mitral annular velocities included early
diastolic annular velocity (E=) and late diastolic annular
velocity (a=). These measurements were performed in accor-
dance with current American Society of Echocardiography
guidelines (21,22). Echocardiographic contrast was used
when studies were technically difficult. The assessment of
mitral and aortic valve regurgitation severity was performed
by means of color Doppler techniques and was based on
current guidelines. The severity of mitral regurgitation was
evaluated using the color flow jet area and classified as mild
(20% of LA area), moderate (20% to 40% of LA area),
and severe (40% of LA area). Aortic regurgitation severity
was assessed by the color jet to LV outflow tract width ratio
and classified as mild (25%), moderate (25% to 64%), and
severe (65%).
Intraobserver and interobserver variability. All the echo-
cardiograms were interpreted by 2 independent readers
(O.W.P., S.G.D.). In order to evaluate the reliability of our
measurements, both interobserver and intraobserver vari-
ability were tested in both of our readers. To assess
intraobserver variability, 1 of the 2 readers performed
echocardiographic measurements in 10 randomly selected
patients in 2 different occasions at least 2 weeks apart.
Interobserver variability among our 2 readers was tested
by the independent evaluation of 10 randomly selected
patients. By means of the Pearson correlation, there was
an excellent correlation among both readers (r  0.98,
p  0.0001). Both intraobserver and interobserver agree-
ment, evaluated by means of intraclass correlation coeffi-
cients, were excellent for the echocardiographic parameters
tested, with intraclass correlation coefficients of 0.99 (95%
confidence interval [CI]: 0.99 to 0.99, p 0.0010) and 0.98
(95% CI: 0.98 to 0.99, p  0.001), respectively.
Statistical analysis. Data were summarized using standard
statistical descriptors such as frequencies, percentages,
means, standard deviations, medians, and percentiles. Cat-
egorical variables were compared by the Pearson chi-square
test or Fisher exact test. As the continuous covariates were
frequently not normally distributed, we decided to present
the results as a median and with interquartile range (IQR)
percentiles (25th percentile, 75th percentile) and to compare
the distributions using a nonparametric test, such as the
Kruskal-Wallis test, followed by post-hoc pairwise compar-
ison by Dunn test. Wilcoxon matched-pairs signed-rank
test was used when appropriate. Changes of select func-
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LVAD Unloading Effects on Cardiac Function May 14, 2013:1985–94tional and structural parameters over time were depicted
using means and confidence intervals. Two-tailed p  0.05
as considered statistically significant. All analyses were
erformed using STATA software (version 12.0, StataCorp
P, College Station, Texas).
esults
atient characteristics and medications. The patient
aseline characteristics at the time of LVAD implantation
re shown in Table 1. The prospective design of our study
llowed us to carefully evaluate the candidates and to
xclude patients with acute HF. Patients in our study had a
edian duration of HF of over 5 years, LV dilation and a
ean LVEF of 18% (median: 16%): all characteristics
onsistent with chronic end-stage HF. Medications used
uring LVAD support included renin-angiotensin-
ldosterone axis inhibitors (n  32, 40%), beta adrenergic
blockers (n  25, 31%), loop diuretics (n  62, 78%),
Patient Characteristics Pre-LVAD ImplantationTable 1 Patient Characteristics Pre-LVAD Implantation
Age, yrs 60 (51, 68)
Male 64 (80)
Body mass index, kg/m2 27 (24, 32)
Diabetes mellitus 22 (28)
Hypertension 33 (41)
Chronic HF etiology
Idiopathic CMP 37 (46)
Ischemic CMP 34 (43)
Valvular CMP 5 (6)
Chemotherapy CMP 3 (4)
Peripartum CMP 1 (1)
Duration of HF symptoms, yrs 5.5 (1, 10)
NYHA functional class
III 29 (36)
IV 51 (64)
LVEF, % 16 (13, 23)
LVEDD, cm 6.6 (5.8, 7.3)
Cardiac index, l/(min · m2) 1.7 (1.4, 2.0)
IABP/Centrimag/ECMO 8 (10)
Inotrope dependence 56 (70)
INTERMACS profile
1 9 (11)
2 12 (15)
3 39 (49)
4 16 (20)
5 3 (4)
6 1 (1)
LVAD indication
BTT 52 (65)
BTD 3 (4)
DT 25 (31)
Values aremedian (25th, 75th percentiles) or n (%). CentriMag (Ventricular Assist System, Thoratec
Corp., Pleasanton, California).
BTD bridge to decision; BTT bridge to transplant; CMP cardiomyopathy; DT destination
herapy; ECMO  extracorporeal membrane oxygenator; HF  heart failure; IABP  intra-aortic
alloon pump; LVAD  left ventricular assist device; LVEDD  left ventricular end-diastolic
iameter; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association;
NTERMACS  Interagency Registry for Mechanically Assisted Circulatory Support.nitrates/hydralazine (n  17, 21%), calcium channel block-
p
ners (n  16, 20%), aspirin (n  77, 96%), clopidogrel (n 
4, 5%), and warfarin (n  78, 98%).
Hemodynamic and biochemical data. Table 2 shows in-
vasive and noninvasive hemodynamic data and biochemical
data before and after LVAD unloading. As expected,
LVAD therapy resulted in a significant increase in cardiac
output and a decrease in filling pressures, pulmonary arterial
pressures, and pulmonary vascular resistance. We noted an
increase in serum sodium, a decrease in serum blood urea
nitrogen and creatinine, and a decrease in serum hemoglo-
bin and total bilirubin after LVAD implantation.
Serial effects on LV structure and systolic function.
Echocardiographic parameters were obtained before and
then serially after LVAD implantation (Table 3, Fig. 1).
The magnitude of systolic functional response during
continuous-flow LVAD unloading was diverse. Overall,
LVEF increased from 17% (IQR: 14% to 23%) at the time
of LVAD implantation to 25% (IQR: 18% to 33%) 6
months later (p  0.01) (Table 3). In 19% of the patients,
the LVEF improved to 40% (Table 3). The LV end-
diastolic and end-systolic volumes decreased significantly as
early as 30 days after LVAD implantation. LV mass
decreased as early as 30 days after LVAD unloading from
114 g/m2 (IQR: 93 to 146 g/m2) to 95 g/m2 (IQR: 71 to
114 g/m2), p  0.05, and continued to do so progressively
ver the 1-year follow-up, but, notably, this decrease was not
eyond the normal reference range (43 to 115 g/m2) (21).
The relative increase in LVEF, defined as “pre-LVAD to
ighest LVEF achieved post-LVAD,” is shown in Figure 2A.
ased on this relative functional response, we identified 4
roups of patients: group 1: LVEF relative increase 25%,
Hemodynamic and Biochemical ProfileB fore and After LVAD UnloadingTable 2 Hemodynamic and Bioch mical ProfileBefore and After LVAD Unloading
Pre-LVAD Post-LVAD p Value
Hemodynamics
Mean BP, mm Hg 79 (74, 86) 89 (81, 99)* 0.0001
HR, beats/min 94 (84, 112) 88 (80, 99) 0.02
RAP, mm Hg 14 (9, 18) 8 (4, 10) 0.0008
PCWP, mm Hg 28 (23, 30) 13 (9, 19) 0.0001
PASP, mm Hg 55 (44, 64) 32 (26, 41) 0.0001
PADP, mm Hg 27 (24, 32) 14 (11, 18) 0.0001
Mean PAP, mm Hg 38 (31, 43) 21 (17, 27) 0.0001
PVR, Woods units 3.0 (1.9, 4.7) 1.8 (1.2, 2.2) 0.0007
Cardiac index, l/(min · m2) 1.7 (1.5, 2.0) 2.4 (2.1, 2.8) 0.0001
Biochemical
Serum sodium, mEq/l 135 (132, 138) 138 (136, 140) 0.0001
Serum BUN, mg/dl 28 (20, 38) 20 (15, 29) 0.0001
Serum creatinine, mg/dl 1.3 (1.0, 1.7) 1.1 (0.9, 1.4) 0.02
Serum bilirubin, mg/dl 1.2 (0.7, 1.6) 0.8 (0.5, 1.2) 0.03
Serum hemoglobin, g/dl 12.5 (11, 14) 11.6 (10, 13) 0.0001
Platelet count, 109/l 182 (144, 236) 207 (152, 288) 0.03
Values are median (25th, 75th percentiles). *The post-LVAD blood pressure is an approximate
systolic/mean blood pressure due to the continuous flow of the LVAD.
BP blood pressure; BUN blood urea nitrogen; HR heart rate; LVAD left ventricular assist
evice; PADP  pulmonary artery diastolic pressure; PAP  pulmonary artery pressure; PASP 
ulmonary artery systolic pressure; PCWP  pulmonary capillary wedge pressure; PVR  pulmo-
ary vascular resistance; RAP  right atrial pressure.
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May 14, 2013:1985–94 LVAD Unloading Effects on Cardiac Functionn  38 (47%); group 2: LVEF relative increase 25% to
50%, n 15 (19%); group 3: LVEF relative increase 51% to
9%, n  18 (23%); and group 4: LVEF relative increase
100%, n  9 (11%). The changes in LVEF over time for
atients with a relative increase in LVEF of 51% to 99%
group 3) and 100% (group 4) are shown in Figures 2B
nd 2C. As shown, the greatest systolic function improve-
ent was achieved within 6 months after LVAD implan-
ation, with little if any further improvement at later time
oints.
The diversity of the systolic functional response to
ontinuous-flow LVAD unloading is shown in Figure 3A,
n which patients were stratified based on the “highest
VEF achieved” after LVAD unloading. We identified 4
roups of patients: group 1: LVEF 20%, n  26 (33%);
roup 2: LVEF 20% to 29%, n 25 (31%); group 3: LVEF
0% to 39%, n  20 (25%); and group 4: LVEF 40%,
 9 (11%). Again, we focused on the patients with greater
unctional improvement (i.e., groups 3 and 4). As shown in
igures 3B and 3C, the greatest systolic functional improve-
ent following LVAD unloading is again achieved within 6
onths after the initiation of this therapy.
Echocardiographic parameters were also recorded during
erial turn-down echocardiograms. Decrease of the LVAD
peed resulted in reduced flow through the LVAD and
ncreased LV loading. The increased loading was confirmed
Serial Echocardiographic Assessment of the Effects of LVAD UnloaTable 3 Serial Echocardiographic Assessment of the Effects of
Parameter
Pre-LVAD
(n  80)
30 Days
(n  68)
60 Days
(n  44)
90
(n
LVEDDI, cm/m2 3.2 (2.9, 3.6) 2.8 (2.3, 3.2)* 2.9 (2.5, 3.2)† 2.9 (2
LVESDI, cm/m2 3.0 (2.6, 3.3) 2.6 (2.0, 3.1)* 2.6 (2.2, 3.0) 2.6 (2
FS, % 8.3 (4.2, 13.5) 8.2 (5.2, 12.9) 8.5 (6.2, 12.3) 7.1 (4
IVSd, cm 0.84 (0.68, 1.1) 0.90 (0.70, 1.10) 0.93 (0.74, 1.16) 0.85 (0
IVSs, cm 1.01 (0.82, 1.22) 1.10 (0.89, 1.27) 1.06 (0.86, 1.23) 1.10 (0
PWd, cm 0.84 (0.70, 1.00) 0.87 (0.70, 1.03) 0.90 (0.71, 1.02) 0.83 (0
PWs, cm 0.98 (0.79, 1.22) 1.02 (0.86, 1.21) 1.05 (0.90, 1.20) 1.00 (0
LV mass, g/m2 114 (93, 146) 95 (71, 114)† 100 (82, 122) 92 (6
LVEDVI, ml/m2 113 (94, 141) 77 (54, 109)* 76 (64, 100)* 86 (6
LVESVI, ml/m2 92 (74, 116) 60 (42, 88)* 60 (46, 81)* 71 (4
LVEF, % 17 (14, 23) 20 (15, 30) 20 (15, 30) 20 (1
LVEF 40% 0 7.4 9.1
RVEDD, cm 4.4 (3.9, 5.2) 4.3 (3.5, 5.0) 4.4 (3.5, 4.9) 4.4 (4
RVOTd, cm 3.9 (3.4, 4.3) 3.7 (3.1, 4.1) 3.6 (3.3, 4.2) 3.7 (3
MR
Mild 34 (42) 33 (48) 18 (41) 21 (4
Moderate 20 (25) 4 (6) 2 (4.5) 2 (4
Severe 16 (20) 1 (1.5) 4 (9) 1 (2
AI
Mild 11 (14) 22 (32) 15 (34) 16 (3
Moderate 1 (1.2) 1 (1.5) 1 (2.3) 2 (4
Severe 0 0 0
Values are median (25th, 75th percentiles) or %, n (%). *p  0.01 versus pre-LVAD; †p  0.05 ve
AI aortic insufficiency; FS fractional shortening; IVSd interventricular septum at end diasto
dimension index; LVEDVI left ventricular end-diastolic volume index; LVESDI left ventricular en
PWd  posterior wall dimension at end diastole; PWs  posterior wall dimension at end systole;
end diastole; other abbreviations as in Table 1.y our assessment of aortic valve opening during the aurn-down echocardiographic studies. During the regular
ull LVAD support, the aortic valve opened rarely, whereas
uring the LVAD turn-down exams, the aortic valve
pened with every beat (data not shown). The improvement
n LV structure and systolic function was sustained under
he increased loading conditions during turn-down echo-
ardiographic studies and is described in detail in Online
able 1. The turn-down studies were well tolerated by most
atients; transient mild HF symptoms were documented in
ess than 3% of the studies, and the symptoms were alleviated
oon after increasing the LVAD speed back to full support.
We carried out a separate analysis on the subset of LVAD
atients who completed 6 months of LVAD unloading,
xcluding patients with shorter duration of support that
ould have been considered inadequate to attest the full
ffects of mechanical unloading. The effects of LVAD
nloading on “relative increase of LVEF” and on the
highest LVEF achieved” for this subset of patients (Online
igures 1 and 2, respectively) were comparable to the
ndings shown in Figures 2 and 3 for the whole study
population. The percentage of patients that achieved LVEF
40% at 6 months was 19% (Online Fig. 2).
Characteristics of patients with greater systolic func-
tional response. In patients with greater functional im-
provement (i.e., groups 3 and 4 vs. groups 1 and 2 of Fig. 3),
here was a nonsignificant trend for younger age (median
on Myocardial Structure and Systolic FunctionUnloading on Myocardial Structure and Systolic Function
120 Days
(n  37)
180 Days
(n  32)
270 Days
(n  24)
365 Days
(n  20)
)† 2.8 (2.4, 3.3)† 2.8 (2.2, 3.4)† 2.6 (2.2, 3.1)* 2.6 (2.2, 3.0)*
) 2.5 (2.1, 3.0)† 2.5 (1.8, 2.9)* 2.2 (1.8, 2.8)* 2.3 (1.9, 2.8)*
.3) 10.5 (5.1, 17.8) 12.5 (6.4, 19.1) 13.4 (5.3, 20.4) 9.3 (5.3, 20.4)
.05) 0.96 (0.80, 1.15) 0.94 (0.81, 1.19) 0.94 (0.71, 1.16) 0.80 (0.66, 1.10)
.23) 1.13 (0.88, 1.25) 1.15 (1.00, 1.30) 1.10 (0.86, 1.20) 0.97 (0.79, 1.20)
.95) 0.81 (0.72, 0.96) 0.92 (0.83, 1.05) 0.79 (0.70, 0.92) 0.77 (0.71, 0.87)
.15) 1.10 (0.90, 1.20) 1.09 (0.94, 1.20) 1.02 (0.80, 1.14) 0.97 (0.84, 1.15)
8)† 88 (68, 124) 111 (74, 134) 92 (52, 106)* 77 (50, 104)*
6)* 82 (61, 110)* 86 (52, 108)* 71 (44, 92)* 69 (45, 93)*
4)† 66 (40, 92)* 64 (35, 90)* 54 (28, 76)* 56 (31, 75)*
) 20 (15, 30) 25 (18, 33)* 25 (17, 36)† 22 (15, 31)
10.8 18.8 20.8 10
) 4.2 (3.7, 4.6) 4.2 (3.9, 4.6) 4.0 (3.3, 4.6) 4.8 (3.5, 5.2)
) 3.6 (3.2, 3.8) 3.7 (3.1, 3.9) 3.5 (3.1, 4.0) 3.8 (3.5, 4.1)
14 (38) 15 (47) 11 (46) 9 (45)
3 (8) 2 (6) 1 (4) 3 (15)
1 (3) 2 (6) 0 2 (10)
13 (35) 11 (34) 13 (54) 10 (50)
2 (5) 5 (16) 1 (4)* 3 (15)
0 0 0 1 (5)
e-LVAD.
 interventricular septum at end systole; LV left ventricle; LVEDDI left ventricular end-diastolic
ic dimension index; LVESVI left ventricular end-systolic volume index; MRmitral regurgitation;
 right ventricular end-diastolic dimension; RVOTd  right ventricular outflow tract dimension atdingLVAD
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LVAD Unloading Effects on Cardiac Function May 14, 2013:1985–94[range: 20 to 81] years; group 3: 58 [range: 15 to 79] years;
group 4: 48 [range: 13 to 74] years; p  NS) and shorter
duration of HF history (median duration in group 1: 5 years;
group 2: 6 years; group 3: 6.5 years; group 4: 1 year; p 
S). The proportion of patients with ischemic and non-
schemic cardiomyopathy was 27% and 73% in group 1, 52%
nd 48% in group 2, 55% and 45% in group 3, and 33% and
7% in group 4, respectively. Therefore, LVAD-induced
unctional improvement was not exclusive to patients with
onischemic cardiomyopathy.
The distribution of medications with direct effects on
ardiac remodeling (e.g., renin-angiotensin-aldosterone axis
nhibitors and beta adrenergic receptor antagonists) was
imilar among the identified 4 groups of LVAD-induced
ystolic function response. Various complications during
VAD support (major bleeding, hemolysis, right heart
ailure, cardiac arrhythmia, device malfunction, hyperten-
ion, major infection, myocardial infarction, renal dysfunc-
ion, etc., as defined by INTERMACS and prospectively
ocumented per our study design) that could affect the
otential for myocardial recovery were also similar among
hese 4 subgroups of patients.
erial effects on LV diastolic function. As shown in Table 4,
e found significant and sustained improvement after
VAD unloading in several parameters of diastolic func-
ion. Specifically, LA size, E-wave deceleration time, septal
=, and E-wave to E= ratio significantly improved as early as
0 days after LVAD unloading, and this improvement
ersisted over time (Fig. 4). Post-LVAD improvements in
V diastolic function were sustained under increased load-
ng conditions induced during serial turn-down echocardio-
raphic studies (Online Table 2).
iscussion
his single-program, prospective study of a large cohort of
VAD patients demonstrates that continuous-flow me-
hanical unloading of the failing human heart results in
ignificant changes at the structural, hemodynamic, and
unctional levels. The study was designed to investigate
hese changes serially and under both decreased and re-
ewed loading conditions induced by turn-down echocar-
iographic studies.
iversity of myocardial changes. The magnitude of the
VAD-induced functional changes was diverse, whereas
emodynamic changes were more uniform. This diversity
n systolic functional response is in agreement with data
rom studies of first-generation LVAD (4 –10,23–27) and
ay reflect the diversity of the population studied in their
ropensity for myocardial functional recovery (HF etiol-
gy: acute vs. chronic HF and ischemic vs. non ischemic
F; extent of pre-LVAD pathologic and molecular myo-
ardial remodeling, etc.) and differences in medical therapy
dded to LVAD therapy (10). The latter is a limitation of
ur study as well. However, the distribution of medicationsFigure 1 Serial Echocardiographic Changes
(A) LVEF (left ventricular ejection fraction). (B) LVEDVI (left ventricular end dia-
stolic volume index). (C) LVESVI (left ventricular end systolic volume index). (D)
LV (left ventricular) mass. Data is presented as means and confidence inter-
vals. *p  0.01 vs. Pre- LVAD; †p  0.05 vs. Pre-LVAD.ith direct effects on cardiac remodeling (e.g., renin-
o
o
F
f
b
b
d
p
s
s
d
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found to be comparable between the identified 4 groups of
LVAD-induced systolic function response.
Our data also show that myocardial functional recovery
after LVAD unloading is not an all-or-nothing phenome-
non. Specifically, a subset of end-stage chronic HF patients
had a marked improvement of their systolic heart function
(i.e., 19% of patients that completed 6 months of mechan-
ical unloading had an LVEF40%) whereas another subset
f patients showed improvement to a degree similar to that
f stable HF outpatients (i.e., “partial recovery”: group 3 of
ig. 3 and Online Fig. 2). The patients with greater
unctional improvement after LVAD unloading tended to
e younger (5,28) and with shorter duration of HF (5,6,28),
ut the correlation of age and duration of HF with recovery
id not reach statistical significance. The small numbers of
atients in these groups prevented us from conducting a
ubgroup analysis. Larger scale studies are needed to draw
olid conclusions on these issues.
Importantly, the RV size as assessed by means of RV
imensions obtained at end-diastole from a RV-focused
Figure 2 Relative Increase in LVEF Defined as “Pre-LVAD to Hi
(A) Relative Increase in LVEF Defined as “Pre-LVAD to Highest LVEF Post-LVAD” (B
99% (group 3). (C) Changes in LVEF over time for patients with a relative increase
dence intervals. *p  0.01 vs. Pre-LVAD; †p  0.05 vs. Pre-LVAD. Abbreviations a
Figure 3 Highest LVEF Achieved After LVAD Unloading
(A) Highest LVEF achieved after LVAD unloading. (B) Changes in LVEF over time fo
over time for patients with highest LVEF achieved 40% (group 4). Data is presen
viations as in Figure 1.apical 4-chamber view (basal RV end-diastolic dimension)
and from a parasternal long-axis view (RV outflow tract)
was found neither to improve nor deteriorate after chronic
LVAD unloading. Regarding valvular abnormalities, the
incidence of moderate and severe mitral regurgitation sig-
nificantly improved after LVAD unloading. However, con-
sistent with other recent reports, we observed an increase in
the incidence of mild and moderate aortic insufficiency.
Given the relatively short duration of our study, we cannot
derive solid conclusions on the effects of chronic LVAD
unloading on the aortic valve.
Impact of HF etiology. The impact of HF etiology on the
prospect of reverse remodeling and myocardial recovery
with mechanical unloading requires further investigation. In
our study, we excluded patients with acute HF, a group of
patients that could confound our findings given that they are
more prone to myocardial recovery without any specific
disease-modifying intervention. Furthermore, it has been
proposed that the patients most likely to show reverse
remodeling and myocardial recovery induced by LVAD
unloading are those with nonischemic cardiomyopathy
LVEF Post-LVAD”
nges in LVEF over time for patients with a relative increase in LVEF of 51% to
EF of 100% (group 4). Data is presented as percentages, means, and confi-
igure 1.
ents with highest LVEF achieved 30% to 39% (group 3). (C) Changes in LVEF
percentages, means, and confidence intervals. *p  0.01 vs. Pre-LVAD. Abbre-ghest
) Cha
in LV
s in Fr pati
ted as
al (l) an
a rial dim
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large areas of noninfarcted myocardium that “remodeled”
over the years could also be considered candidates for
reverse remodelling and myocardial recovery (10,29). Often,
these patients were discharged after their index acute myo-
cardial infarction with a preserved LVEF and no symptoms
of HF to come back later with severely impaired LV systolic
function and overt HF due to remodeling of the nonin-
farcted regions of their myocardium (29). Notably, groups 3
and 4 of Figure 3 (i.e., the patients with the greater
functional improvement) included high percentages of isch-
emic cardiomyopathy patients (55% and 33%, respectively).
Probably the concept of myocardial recovery in ischemic
cardiomyopathy patients deserves further investigation in
larger-scale studies. This approach could combine the exci-
sion of scarred myocardium, using LV reconstruction tech-
niques, with LVAD unloading (10,29). It can be argued
that with this latter approach the initial insult that triggered
Figure 4 Serial Changes on Diastolic Function Echocardiograph
E  mitral valve inflow early velocity, E=  early diastolic motion of the mitral annu
Serial Echocardiographic Assessment of the Effects of LVAD UnloaTable 4 Serial Echocardiographic Assessment of the Effects of
Parameter
Pre-LVAD
(n  80)
30 Days
(n  70)
60 Days
(n  41)
90
(n 
LADI, cm/m2 2.3 (2.2, 2.6) 2.0 (1.9, 2.4)* 2.1 (1.8, 2.4)* 2.0 (1.
LAVI, ml/m2 46 (35, 54) 28 (22, 36)* 32 (22, 39)* 32 (23
E-wave, m/s 1.0 (0.8, 1.1) 0.8 (0.6, 1.0)* 0.8 (0.7, 1.0) 0.8 (0.
A-wave, m/s 0.3 (0.2, 0.5) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.5 (0.
EDT, m/s 133 (112, 165) 175 (137, 220)* 189 (150, 200)* 178 (14
E/A ratio 2.8 (2.1, 4.1) 2.2 (1.2, 3.6) 1.8 (1.0, 3.1) 1.5 (1.
E=-wave (l), m/s 0.08 (0.05, 0.11) 0.09 (0.07, 0.10) 0.11 (0.09, 0.12)† 0.09 (0.
A=wave (l), m/s 0.04 (0.03, 0.06) 0.05 (0.04, 0.08) 0.06 (0.04, 0.09) 0.07 (0.
E/E= (l) 14 (9, 19) 9 (6, 13)† 8 (7, 10)* 10 (6,
E=-wave (s), m/s 0.04 (0.03, 0.06) 0.06 (0.05, 0.09)* 0.07 (0.05, 0.09)* 0.07 (0.
A=-wave (s), m/s 0.04 (0.03, 0.06) 0.04 (0.03, 0.07) 0.06 (0.04, 0.07) 0.06 (0.
E/E= (s) 23 (16, 30) 13 (9, 19)* 11 (10, 15)* 12 (9,
Values are median (25th, 75th percentiles). For between-group comparisons: *p  0.01 versus p
Amitral valve inflow atrial velocity; A= late diastolic motion of the mitral annulus at the later
nnulus at the lateral (l) and septal (s) positions; EDT  E-wave deceleration time; LADI  left atthe cascade of cardiac remodeling progression—the post-
myocardial infarction scar—would be eliminated (10,29). In
contrast, in most nonischemic cardiomyopathy patients, the
initial insult that caused progressive ventricular remodeling
and HF often remains undetermined, most likely persists
despite an initially successful reversal of the process by
mechanical unloading, and might recur and cause further
progression of HF after the termination of LVAD support
(10,29). This may explain why long-term freedom from
recurrent HF in the largest bridge to recovery series in
nonischemic cardiomyopathy patients was 74% and 66% at
3 and 5 years, respectively (5).
Impact of duration of mechanical unloading: myocardial
recovery versus atrophy. In our study, improvements in
LV systolic and diastolic function were incremental, with
the greatest degree of improvement being achieved within 6
months after LVAD implantation. This finding may provide
useful guidance to the design of future bridge-to-recovery
rameters
ata is presented as means and confidence intervals. *p  0.01 vs. Pre-LVAD.
on Left Ventricular Diastolic FunctionUnloading on Left Ventricular Diastolic Function
120 Days
(n  37)
180 Days
(n  32)
270 Days
(n  24)
365 Days
(n  20)
* 2.0 (1.8, 2.5)* 2.2 (1.7, 2.5) 2.1 (1.9, 2.4) 1.9 (1.8, 2.3)*
32 (25, 42)* 25 (19, 39)* 32 (24, 39)* 28 (18, 38)*
0.8 (0.6, 1.1) 0.8 (0.7, 1.1) 0.8 (0.7, 1.0) 1.0 (0.6, 1.2)
† 0.6 (0.4, 0.7)† 0.5 (0.4, 0.7)† 0.6 (0.3, 0.6) 0.6 (0.4, 0.7)
)* 206 (155, 230)* 172 (121, 220)* 200 (167, 220)* 170 (157, 225)
* 1.6 (0.8, 2.3)* 1.6 (1.3, 2.2)† 1.6 (1.1, 2.8)† 1.7 (1.0, 3.3)
1) 0.09 (0.05, 0.12) 0.10 (0.07, 0.13) 0.13 (0.09, 0.15)† 0.12 (0.08, 0.12)
9) 0.06 (0.04, 0.07) 0.06 (0.03, 0.10) 0.09 (0.06, 0.11)† 0.09 (0.06, 0.10)
9 (7, 15) 9 (7, 13) 7 (5, 8)* 10 (6, 11)
9)* 0.07 (0.04, 0.08) 0.07 (0.04, 0.09)* 0.08 (0.06, 0.13)* 0.07 (0.06, 0.10)†
7) 0.05 (0.03, 0.07) 0.05 (0.02, 0.09) 0.07 (0.05, 0.09)† 0.07 (0.05, 0.10)
14 (9, 19)† 12 (9, 19)* 10 (6, 14)* 15 (7, 17)†
; †p  0.05 versus pre-LVAD.
d septal (s) positions; Emitral valve inflow early velocity; E= early diastolic motion of the mitral
ension index; LAVI  left atrial volume index; LVAD  left ventricular assist device.ic Pa
lus. DdingLVAD
Days
48)
8, 2.4)
, 38)*
7, 1.0)
3, 0.8)
1, 212
0, 2.9)
06, 0.1
04, 0.0
12)
05, 0.0
03, 0.0
16)*
re-LVAD
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advanced HF patient without any signs of significant func-
tional improvement during the first few months of LVAD
unloading is not likely to show significant improvement sub-
sequently. Given the long-term outcomes of heart transplan-
tation (30), and the higher likelihood of LVAD-induced
recovery in young HF patients (5,28), a 6-month “LVAD
challenge” before transplant candidacy might be a reasonable
option for programs that are already investigating ways to
improve the long-term outcomes of their younger patients by
saving the transplant therapeutic option for a later stage.
Another issue is the durability of LVAD-induced cardiac
improvement. Data from the pulsatile LVAD era indicated
that prolonged mechanical unloading might be associated
with an initial phase of functional improvement followed by
a later phase of deterioration. Specifically, the LVAD
Working Group found in a multicenter study that pulsatile
LVAD induced significant improvement in LVEF after 30
days of support that progressively decreased to pre-LVAD
measurement at 120 days (4). So far, this is the largest
prospective study (n  67, predominantly bridge-to-
transplant patients) reporting on the LVAD unloading
effects on myocardial function and structure (4). In our
study of 80 continuous-flow LVAD patients, we found no
decrease in LV function with long-term mechanical unload-
ing, but the number of patients studied at long-term
follow-up points was relatively low. This apparent advan-
tage of continuous-flow mechanical unloading warrants
further investigation with larger- and longer-term studies.
A long-standing question, directly related to the afore-
mentioned discussion about the sustainability of LVAD-
induced cardiac improvement, is whether prolonged LVAD
unloading induces regression of cardiac hypertrophy to the
point of atrophy and degeneration. Animal models of
unloading of nonfailing/nonhypertrophic myocardium by
means of heterotopic transplantation (31) or LVAD (32)
suggested that prolonged mechanical unloading could lead
to cardiac myocyte atrophy. Whether this phenomenon
applies exclusively to unloaded nonfailing and nonhypertro-
phic or also to hypertrophic and failing myocardium is
controversial (6,9,33,34). We show that LV mass did
decrease with continuous-flow LVAD unloading, but it
remained within the normal reference range (21). There-
fore, neither the structural nor the functional findings of our
study suggest hypertrophy regression to the point of atrophy
and degeneration. This is in agreement with histological,
ultrastructural (electron microscopy), metabolic, and molec-
ular data we have recently presented (35).
LV-loading conditions. Finally, an important issue is
whether the systolic and diastolic functional changes we
described would be sustained with discontinuation of me-
chanical unloading. The protocol to induce increased load-
ing conditions on the LV used in our study is similar to
published protocols used in bridge-to-recovery LVAD
studies that led to sustained myocardial recovery following
LVAD explantation (6,9,20). An indirect way we used toconfirm that the turn-down studies were effectively increas-
ing the loading conditions on the myocardium was the
continuous assessment of aortic valve opening. We con-
firmed that during our turn-down studies aortic valve
opening occurred with each ventricular systole as opposed to
very rare or no aortic valve opening at all during the regular
full LVAD support. However, the ideal duration of a
turn-down echocardiographic study to reliably evaluate the
“underlying” functional capacity of the LVAD-supported
native heart is not known. Consequently, whether the
changes observed in our study predict the native heart’s
functional capabilities after an eventual LVAD explantation
requires further investigation. Independent of this limita-
tion, the fact that end-stage human failing hearts undergo-
ing a mechanical unloading intervention substantially im-
proved (and importantly, other hearts similarly sick
undergoing the same intervention did not; i.e., responders
and nonresponders) invites in-depth translational and basic
science research efforts to shed light into these differential
functional responses, regardless of their eventual sustain-
ability. This research could offer an important opportunity
to understand the human heart’s potential to respond to
severe injury and recovery function.
Conclusions
Continuous-flow LVAD unloading induced in a subset of
patients, both ischemic and nonischemic, early improve-
ment in myocardial structure and systolic and diastolic
function that was mostly completed within 6 months and
with no evidence of regression subsequently. These new
insights into the degree and time course of the induced
myocardial improvement could be useful in guiding future
research in the field of mechanical unloading and cardiac
recovery.
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